Material Transfer Agreement, ValiRx PLC, 2020-05-01

RNS Number : 6361L
ValiRx PLC
01 May 2020





(“ValiRx”, the “Company” or the “Group”)




London, UK., 1 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that it has signed an agreement with a global Japanese pharmaceutical company to evaluate Valirx’s therapeutic, VAL301, for the purpose to contemplate a potential future license, for its use in the treatment of endometriosis.


The Material Transfer Agreement (“MTA”) covers the evaluation of VAL 301 in a series of preclinical proof of concept and efficacy studies relating to endometriosis.  Studies are also scheduled to consider proprietary delivery methods for the compound.


The Japanese Company has already conducted a thorough review of Valirx’s prior data under terms of a confidentiality agreement, and now wishes to use material provided by Valirx to conduct their own experiments.


By way of context, ValiRx has developed its VAL301 decapeptide for use in the treatment of endometriosis, while the Japanese Company has a range of pre-clinical assays for testing drug candidates for use in the treatment of endometriosis, as well as several commercial and developmental products in women’s health, and other healthcare areas.


To both parties’ mutual potential benefit therefore and under the terms of the MTA, ValiRx will supply the required quantities of compound, while the Japanese sponsor will be responsible for undertaking an agreed programme of work at its own expense.




This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.



For more information, please contact:


ValiRx plc

Tel: +44 (0) 20 7073 2628

Kevin Alexander

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker


Tel: +44 (0) 20 7469 0930

Notes for Editors


About VAL301

VAL301 is derived from ValiRx’s lead compound and is currently in late-stage pre-clinical development as a non-invasive, effective treatment for the hugely debilitating gynaecological condition, endometriosis. ValiRx has established from its pre-clinical studies that VAL301’s specific mode of action has the potential to provide a potent therapeutic effect to manage the symptoms of endometriosis, without side effects, including loss of bone density and/or infertility.


About Endometriosis

Endometriosis is a benign, oestrogen -dependent chronic condition, characterised by endometrial tissue growth outside of the uterus.  Symptoms including heavy painful periods, pain with intercourse and infertility are often severe and are associated with a decreased quality of life for young women. The condition affects an estimated 1 in 10 women during their reproductive years, equating to approximately 176 million women worldwide*, posing a high economic burden.


About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in “precision” medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.


The Company’s business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.


ValiRx’s two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 


Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx’s pipeline-promise to greatly improve outcomes for cancer patients.


The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.